HIMS & HERS HEALTH, INC. (HIMS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 5.96%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 5.96% | Share-based compensation / revenue. Period ending 2026-06-30. $153.64M ÷ $2.58B × 100 ≈ 5.96% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 2.58B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 153.64M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -154.52M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.58B | $153.64M | $-154.52M | (m) | (m) | 5.96% | (m) | (m) |
| 2026-03-31 | (m) | $2.37B | $147.25M | $-30.61M | (m) | (m) | 6.21% | (m) | (m) |
| 2025-12-31 | (m) | $2.35B | $135.24M | $105.61M | (m) | (m) | 5.76% | (m) | (m) |
| 2025-09-30 | (m) | $2.21B | $125.11M | $115.02M | (m) | (m) | 5.66% | (m) | (m) |
| 2025-06-30 | (m) | $2.01B | $109.83M | $125.59M | (m) | (m) | 5.45% | (m) | (m) |
| 2025-03-31 | (m) | $1.78B | $98.15M | $109.90M | (m) | (m) | 5.50% | (m) | (m) |
| 2024-12-31 | (m) | $1.48B | $92.32M | $61.90M | (m) | (m) | 6.25% | (m) | (m) |
| 2024-09-30 | (m) | $1.24B | $85.76M | $42.91M | (m) | (m) | 6.91% | (m) | (m) |
| 2024-06-30 | (m) | $1.07B | $78.14M | $11.98M | (m) | (m) | 7.32% | (m) | (m) |
| 2024-03-31 | (m) | $959.40M | $70.94M | $-8.29M | (m) | (m) | 7.39% | (m) | (m) |
| 2023-12-31 | (m) | $872.00M | $66.08M | $-29.45M | (m) | (m) | 7.58% | (m) | (m) |
| 2023-09-30 | (m) | $792.58M | $60.64M | $-40.66M | (m) | (m) | 7.65% | (m) | (m) |
| 2023-06-30 | (m) | $710.72M | $54.34M | $-52.09M | (m) | (m) | 7.65% | (m) | (m) |
| 2023-03-31 | (m) | $616.37M | $48.13M | $-63.04M | (m) | (m) | 7.81% | (m) | (m) |
| 2022-12-31 | (m) | $526.92M | $42.82M | $-68.70M | (m) | (m) | 8.13% | (m) | (m) |
| 2022-09-30 | (m) | $444.41M | $42.42M | $-78.66M | (m) | (m) | 9.54% | (m) | (m) |
| 2022-06-30 | (m) | $373.75M | $43.31M | $-86.33M | (m) | (m) | 11.59% | (m) | (m) |
| 2022-03-31 | (m) | $320.88M | $41.84M | $-83.55M | (m) | (m) | 13.04% | (m) | (m) |
| 2021-12-31 | (m) | $271.88M | $67.21M | $-115.04M | $0.00 | (m) | 24.72% | (m) | Reported |
| 2021-09-30 | (m) | (m) | (m) | $-87.75M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | $-63.41M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | $-46.98M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | $-4.79M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | $-2.95M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | $-1.06M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.